NMJ proteins were detected with primary monoclonal and polyclonal antibodies specific for ankyrinG (RDI-ANKYRGabmX; Research Diagnostics, Inc., Flanders, NJ); utrophin (NCL-DRP2; Novocastra/Vector Laboratories, Burlingame, CA); α1-syntrophin (SYN258), β1-syntrophin (SYN37), β2-syntrophin (SYN28), rapsyn (1234), α-dystrobrevins DB-1 (670), and DB-2 (DB2) (all gifts from Marvin Adams and Stanley Froehner, University of Washington, Seattle, WA); s-laminin (D7; Joshua Sanes, Washington University, St. Louis, MO); nNOS (DiaSorin, Stillwater, MN); neuregulin (NDF; Jeffrey A. Loeb, Wayne State University, Detroit, MI); erbB2 (Neu:sc-284; Santa Cruz Biotechnologies, Santa Cruz, CA); erbB3 and erbB4 (05-390 and 06-572; Upstate Biotechnology, Lake Placid, NY); agrin (anti-agrin 4, 8 (606051); Regeneron Pharmaceuticals, Tarrytown, NY); and MuSK (Markus Ruegg, University of Basel, Switzerland). The antibody to slow myosin heavy chain (NCL-MHC slow) was obtained from Novocastra/Vector Laboratories. The secondary antibodies, anti-mouse and anti-rabbit IgGs, were obtained from Molecular Probes, Inc.